Subconjunctival mitomycin C as adjunctive therapy before pterygium excision

To evaluate the safety and efficacy of subconjunctival mitomycin C as adjunctive therapy before pterygium surgery. Prospective noncomparative case series. Thirty-six eyes of 36 patients. Thirty-six eyes of 36 patients prospectively received 0.1 ml of 0.15 mg/ml mitomycin C subconjunctivally injected...

Full description

Saved in:
Bibliographic Details
Published inOphthalmology (Rochester, Minn.) Vol. 110; no. 5; pp. 1012 - 1016
Main Authors Donnenfeld, Eric D, Perry, Henry D, Fromer, Susan, Doshi, Sima, Solomon, Renée, Biser, Seth
Format Journal Article
LanguageEnglish
Published New York, NY Elsevier Inc 01.05.2003
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:To evaluate the safety and efficacy of subconjunctival mitomycin C as adjunctive therapy before pterygium surgery. Prospective noncomparative case series. Thirty-six eyes of 36 patients. Thirty-six eyes of 36 patients prospectively received 0.1 ml of 0.15 mg/ml mitomycin C subconjunctivally injected into the head of the pterygium 1 month before bare sclera surgical excision. Recurrence of pterygia. The pterygia resolved in 34 (94%) of 36 eyes, with a recurrence rate of 6% over a mean follow-up of 24.4 months. No wound-healing complication developed in any patient. Subconjunctival mitomycin C is an effective treatment before pterygium excision. Subconjunctival injection allows exact titration of mitomycin C delivery to the activated fibroblasts and minimizes epithelial toxicity.
ISSN:0161-6420
1549-4713
DOI:10.1016/S0161-6420(03)00091-5